PBAC's latest decision on Ivabradine hydrochloride: Not recommended (2009). Considered for Treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm, who are unable to tolerate or have a contraindication to other suitable PBS-listed drugs.
PBAC outcome
Not recommended
Authority Required (STREAMLINED)
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 3 submissions
Submissions
3
first 2007
Submissions
3
2007 → 2009
Eligible population
patients with chronic stable angina due to atherosclerotic coronary artery disease, who also have left ventricular dysfunction (LVEF ≤40%) and a resting heart rate of 70 bpm or greater
Modelled economic evaluation with scenario analysis; ICER range stated in Pre-Sub-Committee Response.
ICER basis
Range aggregates 3 submissions (2007–2009) — not a single base case.
Why PBAC said no
Reasons cited in the latest PSD: No evidence to directly support the restriction requested in the submission; relied on subgroup analysis of a post hoc subgroup; no evidence comparing ivabradine with perhexiline in patients refractory to all other anti-angina therapy; insufficient basis to recommend listing for either requested restriction
Submission history
Nov 2007: Not recommended · Authority Required — ICER $75k/QALY